Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00984919|
Recruitment Status : Completed
First Posted : September 25, 2009
Last Update Posted : February 15, 2016
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Other: high performance liquid chromatography Other: laboratory biomarker analysis Other: mass spectrometry|
- To identify a potential novel marker of prostate cancer in the blood and urine, 11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection of early relapse in patients previously treated for early-stage prostate cancer.
OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary 11-dh-TXB2 levels by HPLC and tandem-mass spectrometry.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Observational Model:||Case Control|
|Official Title:||Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis|
|Study Start Date :||November 2009|
|Primary Completion Date :||January 2011|
|Study Completion Date :||February 2011|
- Identification of 11-dh-TXB2 in the blood and urine [ Time Frame: 2 to 4 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00984919
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Principal Investigator:||Elisabeth I. Heath, MD||Barbara Ann Karmanos Cancer Institute|